# IMC-002

Source: https://onco.cc/drugs/imc-002/  
OnCo record `imc-002` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMC-002 is an experimental monoclonal antibody from ImmuneOncia Therapeutics, in phase 1 trials for advanced solid tumours and lymphoma.

## Summary

IMC-002 is a monoclonal antibody (fully human IgG1) from ImmuneOncia Therapeutics. An anti-CD47 antibody that blocks CD47 binding to SIRP-alpha so macrophages engulf cancer cells; the company says its affinity is tuned to avoid binding red blood cells. Its furthest stage is phase 1, for advanced solid tumours and lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: IMC-002
- Modality: Monoclonal antibody (fully human IgG1)
- Mechanism: An anti-CD47 antibody that blocks CD47 binding to SIRP-alpha so macrophages engulf cancer cells; the company says its affinity is tuned to avoid binding red blood cells.

## Sources

- ImmuneOncia Therapeutics: immuneoncia.com: https://www.immuneoncia.com/en/m25.php
- ImmuneOncia Therapeutics: immuneoncia.com: https://www.immuneoncia.com/en/m23.php
- ClinicalTrials.gov: trials of IMC-002: https://clinicaltrials.gov/search?intr=IMC-002

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [CD47](https://onco.cc/targets/cd47/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)
- trials: [A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy](https://onco.cc/trials/nct05276310/), [A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas](https://onco.cc/trials/nct04306224/)

---
JSON: https://onco.cc/api/v1/entities/imc-002.json